What is Deep Genomics?
Deep Genomics is revolutionizing drug development by integrating artificial intelligence, RNA biology, and automation. The company's proprietary AI platform is designed to accelerate the discovery of RNA therapies by deciphering complex biological data and pinpointing novel therapeutic targets. By focusing on the underlying genetic causes of diseases, Deep Genomics aims to create highly specific and effective treatments, expanding the therapeutic landscape for conditions previously considered untreatable. Their commitment to understanding RNA biology positions them as a key innovator in precision medicine.
How much funding has Deep Genomics raised?
Deep Genomics has raised a total of $196.7M across 3 funding rounds:
Angel/Seed
$3.8M
Series A
$13M
Series C
$180M
Angel/Seed (2015): $3.8M with participation from Bloomberg and True Ventures
Series A (2017): $13M led by True Ventures and Khosla Ventures Acquisition
Series C (2021): $180M supported by Fidelity Management & Research Company LLC, SoftBank Vision Fund 2, and CPP Investments
Key Investors in Deep Genomics
True Ventures
True Ventures is a venture capital firm that specializes in partnering with early-stage technology and artificial intelligence companies, providing essential capital and strategic guidance.
Khosla Ventures Acquisition
Khosla Ventures is a venture capital firm focused on breakthrough technologies across various sectors including AI, fintech, and sustainable energy, offering venture assistance and strategic advice.
CPP Investments
CPP Investments, formerly Canada Pension Plan Investment Board, is a professional investment management organization that holds or owns securities of companies, focusing on long-term growth and value.
What's next for Deep Genomics?
The substantial enterprise-level funding, including the recent strategic investment, positions Deep Genomics for significant expansion and accelerated research and development. This capital infusion is likely to fuel the advancement of its therapeutic pipeline, enabling the company to move more drug candidates through clinical trials and towards market approval. Furthermore, the backing suggests a strong market validation of Deep Genomics' AI-driven approach to tackling complex genetic disorders, potentially leading to strategic partnerships and further innovation in the biotechnology sector.
See full Deep Genomics company page
